Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor | Zendy

Vincent Vuiblet | Zendy; Philippe Birembaut | Zendy; Abel François | Zendy; C. Cordonnier | Zendy; LaureHélène Noël | Zendy; Jean Michel Goujon | Zendy; F Paraf | Zendy; M.C. Machet | Zendy; S. Girardot-Seguin | Zendy; Y Lebranchu | Zendy; Philippe Rieu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sirolimus-based regimen is associated with decreased expression of glomerular vascular endothelial growth factor

Author(s) -

Vincent Vuiblet,

Philippe Birembaut,

Abel François,

C. Cordonnier,

LaureHélène Noël,

Jean Michel Goujon,

F Paraf,

M.C. Machet,

S. Girardot-Seguin,

Y Lebranchu,

Philippe Rieu

Publication year - 2011

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfr261

Subject(s) - medicine , sirolimus , vascular endothelial growth factor , regimen , vascular access , vascular endothelial growth factor a , vegf receptors , hemodialysis , urology

Sirolimus (SRL) is a potent immunosuppressant used in organ transplantation. It is known to decrease vascular endothelial growth factor (VEGF) synthesis, making it an interesting treatment option for transplant patients who develop Kaposi sarcoma or other malignant diseases. Because VEGF plays a key role in glomerular function and vascular remodelling, we determined the effect of SRL on renal VEGF expression.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research